Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 701–800 of 1,002
Rosenberg, Y. J., Adams, R. J., Hernandez-Abanto, S., Jiang, X., Sun, W., Mao, L., & Lee, K. D. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.09.021 · Cited by 18
Jeong, Y. R., Kim, S. Y., Park, Y. S., & Lee, G. M. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.013 · Cited by 18
Extrinsic and Intrinsic Modulators of Anaphylaxis
Carter, M. C., Park, J., Vadas, P., & Worm, M. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.05.015 · Cited by 17
Dunbar, N. M., Kaufman, R. M., Bary, K. S., Bellairs, G., Cohn, C. S., Angelot‐Delettre, F., Ditcham, S., Duarte, G. D. C., Ellison, A., Fachini, R. M., et al. (2025) · Transfusion · doi:10.1111/trf.18338 · Cited by 17
New Challenges in Drug Allergy: the Resurgence of Excipients
Díaz, M. V., Oribe, I. V., Torrence, D. D., Alfonso, P. H., & Gallardo, E. A. (2022) · Current Treatment Options in Allergy · doi:10.1007/s40521-022-00313-6 · Cited by 19
Chan, E. W., LaFleur, B., Rothenberg, M. L., Merchant, N. B., Lockhart, A. C., Trivedi, B., Chung, C. H., Coffey, R. J., & Berlin, J. D. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181fe46a1 · Cited by 17
Self-citationFuture directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
Pal, S. K., & Figlin, R. A. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0172-y · Cited by 17
O-xylosylation in a Recombinant Protein is Directed at a Common Motif on Glycine–Serine Linkers
Spencer, D., Novarra, S., Zhu, L., Mugabe, S., Thisted, T., Baca, M., DePaz, R. A., & Barton, C. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23733 · Cited by 17
Isotype‐specific glycosylation analysis of mouse IgG by LC‐MS
Maresch, D., & Altmann, F. (2016) · PROTEOMICS · doi:10.1002/pmic.201500367 · Cited by 20
Mammalian meat allergy following a tick bite: a case report
Jackson, W. L. (2018) · Oxford Medical Case Reports · doi:10.1093/omcr/omx098 · Cited by 17
Kobayashi, H., Masuda, Y., Takaya, H., Kubo, T., & Otsuka, K. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01002 · Cited by 17
Ballow, M. C., Akdiş, C. A., Casale, T. B., Wardlaw, A. J., Wenzel, S. E., Ballas, Z. K., & Lötvall, J. O. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.046 · Cited by 17
Seeking alternative biological therapies: The future of targeted molecular treatment
Lorch, J. H., Posner, M. R., Wirth, L. J., & Haddad, R. I. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.08.009 · Cited by 19
Dupont, B., Mariotte, D., Clarisse, B., Galais, M., Bouhier‐Leporrier, K., Grellard, J., Mauff, B. L., Reimund, J., & Gervais, R. (2014) · Future Oncology · doi:10.2217/fon.14.153 · Cited by 19
Accurate assessment of alpha‐gal syndrome using cetuximab and bovine thyroglobulin‐specific IgE
Sim, D. W., Lee, J. S., Park, K. H., Jeong, K. Y., Ye, Y., Lee, J., & Park, J. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201601046 · Cited by 19
Diagnostik des α‑Gal-Syndroms: Aktuelle Standards, Fallstricke und Perspektiven
Weins, A. B., Eberlein, B., & Biedermann, T. (2019) · Der Hautarzt · doi:10.1007/s00105-018-4288-1 · Cited by 17
An, Q., Zheng, Y., Zhao, Y., Liu, T., Guo, H., Zhang, D., Qian, W., Wang, H., Guo, Y., Hou, S., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s170913 · Cited by 17
Anaphylaxis: implications of monoclonal antibody use in oncology.
Gleich, G. J., & Leiferman, K. M. (2009) · PubMed · Cited by 17
Gasek, N., Dearborn, J., Enes, S. R., Pouliot, R., Louie, J., Phillips, Z., Wrenn, S., Uhl, F. E., Riveron, A., Bianchi, J., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121029 · Cited by 16
Platts‐Mills, T. A. E., Workman, L. J., Richards, N. E., Wilson, J. M., & McFeely, E. M. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.09.039 · Cited by 18
Self-citationSpillner, E., Blank, S., & Jakob, T. (2012) · Allergo Journal · doi:10.1007/s15007-012-0128-2 · Cited by 16
Galili, U. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186702 · Cited by 17
Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease
Smith, B. R. E., Black, K. R., Bermingham, M. D., Agah, S., Glesner, J., Versteeg, S. A., van Ree, R., Pena-Amelunxen, G., Aglas, L., Smith, S. A., et al. (2023) · Frontiers in Allergy · doi:10.3389/falgy.2023.1270326 · Cited by 17
IgE and anaphylaxis specific to the carbohydrate alpha-gal depend on IL-4
Hils, M., Hoffard, N., Iuliano, C., Kreft, L., Chakrapani, N., Swiontek, K., Fischer, K., Eberlein, B., Köberle, M., Fischer, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.12.003 · Cited by 20
Leveraging Cross-Linking Mass Spectrometry for Modeling Antibody–Antigen Complexes
Ianni, A. D., Ianni, A. D., Cowan, K. J., Barbero, L. M., & Sirtori, F. R. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00816 · Cited by 17
Alpha-gal syndrome and the gastrointestinal reaction: a narrative review
Propst, S. B. H., & Thompson, D. K. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1535103 · Cited by 17
Schiestl, M., Roy, N., Trieb, M., Park, J. P., Guillén, E., Woollett, G. R., & Wolff‐Holz, E. (2025) · BioDrugs · doi:10.1007/s40259-025-00733-1 · Cited by 16
Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires
Bouché, O., Scaglia, E., Reguiaï, Z., Singha, V., Brixi‐Benmansour, H., & Lagarde, S. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.02.008 · Cited by 16
State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Faber, M. A., Sabato, V., Witte, L. D., Gasse, A. L. V., Hagendorens, M. M., Leysen, J., Bridts, C. H., Clerck, L. S. D., & Ebo, D. G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990046 · Cited by 19
Panitumumab: A safe option for oncologic patients sensitized to galactose-α-1,3-galactose
Caponetto, P., Biedermann, T., Yazdi, A. S., & Fischer, J. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.06.015 · Cited by 16
Immunogenicity-unwanted immune responses to biological drugs – can we predict them?
Matucci, A., Nencini, F., Vivarelli, E., Bormioli, S., Maggi, E., & Vultaggio, A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772053 · Cited by 17
Keshavarz, B., Wiencek, J. R., Workman, L. J., Straesser, M. D., Muehling, L. M., Canderan, G., Drago, F., Bonham, C. A., Sturek, J. M., Ramani, C., et al. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514203 · Cited by 16
Self-citationPark, K. H., Lee, J., Beom, S., Shin, S. J., Ahn, J. B., Kim, S., Lee, J., & Park, J. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100553 · Cited by 16
Capillary (Gel) Electrophoresis-Based Methods for Immunoglobulin (G) Glycosylation Analysis
Cajic, S., Hennig, R., Burock, R., & Rapp, E. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_4 · Cited by 17
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
Clemmons, A. B., Gandhi, A. P., Clarke, A., Jimenez, S., Le, T. T. T., & Ajebo, G. H. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.8.4 · Cited by 16
Idiopathic anaphylaxis: Diagnosis and management
Burrows, A. G., & Ellis, A. K. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210081 · Cited by 17
Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
Goulet, D. R., Chatterjee, S., Lee, W.-P., Waight, A. B., Zhu, Y. Z., & Mak, A. N.-S. (2022) · Antibodies · doi:10.3390/antib11010006 · Cited by 16
Strategies to mitigate the toxicity of cancer therapeutics
Kahn, A. M., Blenman, K., Sonis, S. T., & Lustberg, M. B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.02.006 · Cited by 19
Plum, M., Tjerrild, L., Raiber, T., Bantleon, F. I., Bantleon, S., Miehe, M., Jabs, F., Seismann, H., Möbs, C., Pfützner, W., et al. (2022) · Allergy · doi:10.1111/all.15417 · Cited by 16
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 17
Liao, K., Mackenzie, H. S., Ait‐Oudhia, S., Manimaran, S., Zeng, Y., Akers, T., Yun, T., & Pena, J. D. O. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3116 · Cited by 16
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
Fuloria, J. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s31412 · Cited by 17
Chung, C. H., & O’Neil, B. H. (2009) · PubMed · Cited by 16
Self-citationIgE reactivity to carbohydrate moieties of glycoproteins in wheat allergy
Song, T. W., Hong, J. Y., Lee, K. E., Kim, M. N., Kim, Y. H., Lee, S., Kim, K. W., Sohn, M. H., & Kim, K.-E. (2015) · Allergy and Asthma Proceedings · doi:10.2500/aap.2015.36.3815 · Cited by 16
Fiedler, W., Cresta, S., Schulze‐Bergkamen, H., Dosso, S. D., Weidmann, J., Tessari, A., Baumeister, H., Danielczyk, A., Dietrich, B., Goletz, S., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000303 · Cited by 16
New Opportunities in Glycan Engineering for Therapeutic Proteins
Zhong, X., D’Antona, A. M., Scarcelli, J. J., & Rouse, J. C. (2022) · Antibodies · doi:10.3390/antib11010005 · Cited by 17
Alternate dosing of cetuximab for patients with metastatic colorectal cancer.
Hubbard, J. M., & Alberts, S. R. (2013) · Europe PMC (PubMed Central) · Cited by 18
Biologics in asthma: difficulties and drawbacks
Bousquet, J. J., Chiron, R., & Humbert, M. J. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802496928 · Cited by 17
Platts‐Mills, T. A. E., & Cooper, P. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.068 · Cited by 16
Self-citationWallace, R. P., Refvik, K. C., Antane, J. T., Brünggel, K., Tremain, A. C., Raczy, M. M., Alpar, A. T., Nguyen, M., Solanki, A., Slezak, A. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101345 · Cited by 17
Lai, C., Chen, M., Fraser, S., Wang, J. C., McAfee, S., Speaks, E., Simeone, N., Rodriguez, J., Stefan, C., DeStefano, L., et al. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00993-9 · Cited by 15
Jeimy, S. B., Wong, T., Ben‐Shoshan, M., Copaescu, A. M., Isabwe, G. A. C., & Ellis, A. K. (2025) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00936-1 · Cited by 21
Host cell protein-mediated adjuvanticity and immunogenicity risks of biotherapeutics
Panikulam, S., Morgan, H., Gutknecht, M., Villiger, T. K., Lebesgue, N., & Karle, A. C. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108575 · Cited by 16
Fletcher, E. A. K., Eltahir, M., Lindqvist, F., Rieth, J., Törnqvist, G., Leja-Jarblad, J., & Mangsbo, S. M. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.021 · Cited by 17
Coping with cross-reactive carbohydrate determinants in allergy diagnosis
Altmann, F. (2016) · Allergo Journal · doi:10.1007/s15007-016-1104-z · Cited by 15
Cai, Z., Fu, T., Nagai, Y., Lam, L., Yee, M., Zhu, Z., & Zhang, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3920 · Cited by 15
Clinical Development of Biosimilars: an Evolving Landscape
Subramanyam, M. (2013) · Bioanalysis · doi:10.4155/bio.13.5 · Cited by 15
Dorokhov, Y. L., Sheshukova, E. V., Kosobokova, E. N., Shindyapina, A. V., Kosorukov, V. S., & Komarova, T. V. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916080058 · Cited by 16
Liu, T., Guo, H., Zhu, L., Zheng, Y., Xu, J., Guo, Q., Zhang, D., Qian, W., Dai, J., Guo, Y., et al. (2016) · Chromatographia · doi:10.1007/s10337-016-3173-2 · Cited by 16
Houchens, N., Hartley, S. E., Commins, S. P., Claar, D. D., & Saint, S. K. (2021) · New England Journal of Medicine · doi:10.1056/nejmcps2017588 · Cited by 18
Dupont, B., Mariotte, D., Moldovan, C., Grellard, J., Vergnaud, M.-C., Laroche, D., & Gervais, R. (2014) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s13897 · Cited by 15
Revisión de las reacciones de hipersensibilidad a antineoplásicos
Cortijo‐Cascajares, S., Jiménez-Cerezo, M. J., & de Tejada, A. H. (2012) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.02.004 · Cited by 15
Drug allergy and hypersensitivity: still a hot topic
Bousquet, P., Demoly, P. M., & Romano, A. G. (2009) · Allergy · doi:10.1111/j.1398-9995.2008.01960.x · Cited by 17
Manabe, S., Iwamoto, S., Nagatoishi, S., Hoshinoo, A., Mitani, A., Sumiyoshi, W., Kinoshita, T., Yamaguchi, Y., & Tsumoto, K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06558 · Cited by 14
Properties of protein formulations
Mach, H., Meyer, B. K., & Shameem, M. (2012) · Elsevier eBooks · doi:10.1533/9781908818102.47 · Cited by 14
Chamberlain, P. (2014) · Biosimilars · doi:10.2147/bs.s50012 · Cited by 14
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
Lo, L. L., Patel, D., Townsend, A. R., & Price, T. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1112787 · Cited by 15
Schneider, A. K., Vainshtein, I., Roskos, L. K., Chavez, C., Sun, B., & Liang, M. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.05.007 · Cited by 14
Harmonization and Standardization of Immunogenicity Assessment of Biotherapeutic Products
Wadhwa, M., & Thorpe, R. (2019) · Bioanalysis · doi:10.4155/bio-2019-0202 · Cited by 14
State-of-the-Art Glycomics Technologies in Glycobiotechnology
Pralow, A., Cajic, S., Alagesan, K., Kolarich, D., & Rapp, E. (2020) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2020_143 · Cited by 15
He, E., Quan, W., Luo, J., Liu, C., Zheng, W., & Shen, Q. W. (2023) · Toxins · doi:10.3390/toxins15020132 · Cited by 14
Allergische Soforttypreaktionen und kreuzreaktive Kohlenhydratepitope (CCD)*
Jappe, U., Petersen, A., & Raulf, M. (2013) · Allergo Journal · doi:10.1007/s15007-013-0015-5 · Cited by 14
Using a Risk Assessment Process to Determine Criticality of Product Quality Attributes
Schenerman, M. A., Axley, M. J., Oliver, C. N., Ram, K., & Wasserman, G. F. (2008) · Wiley eBooks · doi:10.1002/9780470466315.ch4 · Cited by 14
Prendergast, G. C., & Metz, R. A. (2012) · OncoImmunology · doi:10.4161/onci.21358 · Cited by 15
Chung, C. H., Rudek, M. A., Kang, H., Marur, S., John, P., Tsottles, N., Bonerigo, S., Veasey, A., Kiess, A. P., Quon, H., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.020 · Cited by 14
Self-citationHuman Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
Hart, F., Danielczyk, A., & Goletz, S. (2017) · Bioengineering · doi:10.3390/bioengineering4020042 · Cited by 14
Wong, X. L., & Sebaratnam, D. F. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14208 · Cited by 16
α-Gal and other recent findings that have informed our understanding of anaphylaxis
Wilson, J. M., & Platts‐Mills, T. A. E. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.11.024 · Cited by 14
Self-citationCharacterization of Vancomycin Reactions and Linezolid Utilization in the Pediatric Population
Lin, S. K., Mulieri, K. M., & Ishmael, F. T. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.12.022 · Cited by 14
Alpha-gal allergy after a tick bite in Austria
Pisazka, V., Duscher, G. G., Hodžić, A., Reider, N., & Allerberger, F. J. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1506-5 · Cited by 15
Hypersensitivity reactions to biologics used in rheumatology
Matucci, A., Nencini, F., Maggi, E., & Vultaggio, A. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1684264 · Cited by 14
Roselló, S., Blasco, I., Fabregat, L. G., Cervantes, A. M. R., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy158 · Cited by 15
In Vivo and In Vitro Diagnostic Methods in the Evaluation of Food Allergy
Bock, S. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1992-5.00013-2 · Cited by 13
In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
Saporiti, S., Bianchi, D., Mariem, O. B., Rossi, M., Guerrini, U., Eberini, I., & Centola, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429600 · Cited by 14
Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck
Pancari, P. A., & Mehra, R. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.03.004 · Cited by 13
Antibodies as stratagems against cancer
Papageorgiou, L., Cuong, N. T., & Vlachakis, D. P. (2015) · Molecular BioSystems · doi:10.1039/c5mb00699f · Cited by 13
Shi, Y., Li, J., Xu, J., Sun, Y. P., Wang, L., Cheng, Y., Liu, W. Y., Sun, G., Chen, Y., Bai, L., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0374-8 · Cited by 13
Product-Related Factors and Immunogenicity of Biotherapeutics
Krishna, M. (2019) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-019-09423-2 · Cited by 14
Alpha-Gal on the Protein Surface Hampers Transcytosis through the Caco-2 Monolayer
Ristivojević, M. K., Grundström, J., Apostolović, D., Radomirović, M., Jovanović, V. B., Radoi, V., Kiewiet, M. B. G., Vukojević, V. B., Veličković, T. Ć., & van Hage, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165742 · Cited by 13
Yuile, A., Fanuli, C., van Nunen, S., Diakos, C. I., Clarke, S. J., Steiner, C., Macmillan, R., Oatley, M., & Pavlakis, N. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13465 · Cited by 14
Eller, E., Skov, P. S., Baumann, K., Hilger, C., Ollert, M. W., & Bindslev‐Jensen, C. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14054 · Cited by 13
Stewart, M. D., McCall, B. B., Pasquini, M. C., Yang, A. S., Britten, C. D., Chuk, M. K., de Claro, R. A., George, B., Gormley, N. J., Horowitz, M. M., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.01.004 · Cited by 13
Anaphylaxis: Advances in the Past 10 Years
Weiler, C. R., Schrijvers, R., & Golden, D. B. K. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.019 · Cited by 14
Ianni, A. D., Barbero, L. M., Fraone, T., Cowan, K. J., & Sirtori, F. R. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115500 · Cited by 14
Alpha-Gal Syndrome: A Novel and Increasingly Common Cause of Anaphylaxis
Edlow, J. A. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2023.08.491 · Cited by 14
Gastropod Allergy: A Comprehensive Narrative Review
Mederos‐Luis, E., Guedes, P. P., Pineda, F., Sánchez‐Machín, I., & González‐Pérez, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060355 · Cited by 13
Confirmatory Immunogenicity Assays
Wakshull, E., & Coleman, D. R. (2011) · Wiley eBooks · doi:10.1002/9781118075685.ch6 · Cited by 13
Glycosylation of Therapeutic IgGs
Mimura, Y., Jefferis, R., Mimura‐Kimura, Y., Abrahams, J. L., & Rudd, P. M. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch3 · Cited by 14
Wollacott, R., Casaz, P., Morin, T. J., Zhu, H. L., Anderson, R. S., Babcock, G. J., Que, J., Thomas, W. D., & Ozturk, S. S. (2013) · mAbs · doi:10.4161/mabs.26192 · Cited by 13
Evaluation and Validation of Diagnostic Tests for Guiding Therapeutic Decisions
Landais, P., Méresse, V., Ghislain, J.-C., Arnaud, O., Bibeau, F., Cellier, D., d’Enfert, J., Eberlé, F., Goestchel, A., Grognet, J., et al. (2009) · Therapies · doi:10.2515/therapie/2009028 · Cited by 13
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.